menu
    • menu
    [{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series B Financing","leadProduct":"ELA026","moa":"SIRP","graph1":"Immunology","graph2":"Phase I","graph3":"Electra Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Electra Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"Electra Therapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"ELA026","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Electra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Electra Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Electra Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Electra Therapeutics

    Menu

    Electra Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Electra Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Electra Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELA026

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Electra Gets FDA Orphan Status for ELA026 in Hemophagocytic Lymphohistiocytosis

                            Details : ELA026 is a first-in-class monoclonal antibody that targets SIRP on the cell surface. It is in clinical development for the treatment of secondary hemophagocytic lymphohistiocytosis.

                            Brand Name : ELA026

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 30, 2024

                            Lead Product(s) : ELA026

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Electra Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Electra Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ELA026

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Westlake Village BioPartners

                            Deal Size : $84.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Electra Therapeutics Announces $84 Million Series B Financing and Unveils Its Novel SIRP Targeted Therapies fo...

                            Details : Proceeds from the financing will be used to continue advancing ELA026 in clinical trials for sHLH and other immunological diseases. The funding will also support advancement of an additional preclinical pipeline program targeting SIRP in immunology.

                            Brand Name : ELA026

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 16, 2022

                            Lead Product(s) : ELA026

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Westlake Village BioPartners

                            Deal Size : $84.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth